Drug Characteristics
  • Formulation

    Injection: 500 mg vial

    Intraocular implants

  • Dose

    CMV retinitis, colitis, oesophagitis treatment: 5 mg/kg IV twice a day for 14–21 days

    IV maintenance treatment: 5 mg/kg IV once a day 7 days a week or 6 mg/kg IV once a day for 5 days each week

    Direct intraocular injection: Usual injection prepared as 2 mg/0.1 ml (0.1 ml injected). Injection frequency varied according to response

  • Side Effects

    Myelosuppression – neutropenia, thrombocytopenia; rash; CNS effects including fitting; abnormal LFTs

  • Interactions

    Additive toxicity with other myelosuppressive drugs e.g. zidovudine, cotrimoxazole

  • Renal

    GFR (ml/min)

    Induction IV dose:

    >70 5 mg/kg every 12 hours

    50–69 2.5 mg/kg every 12 hours

    25–49 2.5 mg/kg/day

    10–24 1.25 mg/kg/day

    <10 1.25 mg/kg/day after dialysis

  • Hepatic

    No dose recommendations

  • Pregnancy

    Compatible – Maternal Benefit >> Embryo-Foetal Risk

  • Other Information